Tivic Health, a bioelectronic medicine company, announced its financial results for the second quarter of 2024, highlighting its commitment to investing in vagus nerve stimulation (VNS) for future growth.
Tivic announced positive results from Phase 1 trials of a new, non-invasive VNS approach. The company believes this breakthrough holds significant potential for addressing various medical conditions.
Tivic reported improved gross margins for its ClearUP product line, increased revenue per marketing dollar spent, and reduced operating expenses. These improvements reflect the company’s efforts to optimize its existing operations.
Tivic is partnering with The Feinstein Institute of Bioelectronic Medicine to refine its VNS program. The company is also investing in intellectual property to strengthen its position in this high-growth area.
Tivic’s financial and operational performance for the first half of 2024 will be detailed in its Quarterly Report on Form 10-Q to be filed on August 14, 2024.
Source link: http://www.businesswire.com/news/home/20240814989979/en/Tivic-Reports-Second-Quarter-2024-Financial-Results
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
